

Convenient Procedures for Synthesis of Ciproxifan, a Histamine H₃-Receptor Antagonist

Holger Stark

Institut für Pharmazie, Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195 Berlin, Germany

Key Words: Cyclopropanes; etherifications; Mitsunobu reactions; histamine H₃ receptors; antagonists

Summary

Cyclopropyl 4-(3-(1*H*-imidazol-4-yl)propyloxy)phenyl methanone (ciproxifan) is a novel reference antagonist for the histamine H₃ receptor. Despite the former Mitsunobu reaction the actual key reaction for preparation based on S_NAr for acylated fluoroaromatics with an additional cyclization in a one-pot procedure needs no chromatographic purification steps and results in good yields.

Ciproxifan (cyclopropyl 4-(3-(1*H*-imidazol-4-yl)propyloxy)phenyl methanone) is a novel reference histamine H₃-receptor antagonist with high potency and selectivity [1]. This compound was obtained by Mitsunobu reaction of imidazolyl trityl-protected 3-(1*H*-imidazol-4-yl)propanol prepared in four steps from urocanic acid with cyclopropyl 4-hydroxyphenyl methanone and following acidic deprotection (Figure 1) [2,3]. Although this reaction sequence could be performed in total yield of about 80% the phenol precursor had to be prepared by Friedel-Crafts-alkylation of phenol or by ether cleavage of the corresponding commercially available 4-methoxyphenyl methanone. Not counting the high costs of the educts including the coupling reagents, the reaction needed two separate chromatographic separations that made this procedure work consuming and unattractive for industrial synthesis. Alternative methods like Williamson synthesis with 4-(3-chloropropyl)-1*H*-imidazole failed because of intramolecular cyclization [4].




Figure 1. Synthesis of ciproxifan given in the literature [3].

In a first attempt nucleophilic exchange reaction was performed with trityl-protected 3-(1*H*-imidazol-4-yl)propanolate and cyclopropyl 4-fluorophenyl methanone in toluene. Work up by extraction, detritylation, and additional extrac-




Figure 2. Improved synthesis procedures for ciproxifan.

tion resulted in a 40% overall yield of the desired product (Figure 2, I). Despite the reduced yields total costs and work expenditure of this procedure were much lower than that of the Mitsunobu way strategy.

Further improvement was performed with the introduction of 4-chloro-4'-fluorobutyrophenone, a versatile, moderately priced synthon well known in the synthesis of neuroleptics, e.g., haloperidol [5]. Reacting this synthon with the alcoholate in an excess of sodium hydride resulted in the same intermediate as described before in the same yield (Figure 2, II). A similar work-up procedure also resulted in 40% overall yields. In this one-pot synthesis the nucleophilic exchange reaction and the formation of the cyclopropyl moiety [6] took place simultaneously. The cyclopropyl ketone moiety proved to be stable under both basic and acidic conditions applied. With larger batches (20–200 mmol) only traces of the corresponding 4-oxobutanol derivative were identified [7].

The improved synthesis procedure for ciproxifan using 4-chloro-4'-fluorobutyrophenone under basic conditions of S_NAr reactions is a simple cost-effective procedure, which can be carried out also in scaling up for industrial synthesis of larger amounts [8].

Acknowledgement

Skilful technical assistance of M. Berg and T. Rudolf is greatly acknowledged. This work was supported by the Biomedical & Health Research Programme BIOMED of the European Union and by the Verband der Chemischen Industrie, Fonds der Chemischen Industrie (Frankfurt/Main, Germany).

Preparation Procedure

Freshly prepared sodium 3-(1-triphenylmethyl-1*H*-imidazol-4-yl)propanolate (5 mmol) was heated with NaH (25 mmol, 60% suspension in mineral oil) and 4-chloro-4'-fluorobutyrophenone (10 mmol) in toluene (40 ml) for 48 h under reflux. The mixture was evaporated to dryness, 2N HCl (30 ml) was carefully added as well as THF (10 ml), and heating at

70 °C was continued for 2 h. This mixture was concentrated under reduced pressure, triphenyl methanol filtered off, and the residue extracted with Et₂O (3 × 20 ml). The aqueous phase was basified with potassium carbonate and extracted with CH₂Cl₂ (3 × 20 ml). The combined organic extracts were dried (Na₂SO₄), evaporated, transformed into hydrogen maleates and crystallized from Et₂O/EtOH.

The reaction of sodium 3-(1-triphenylmethyl-1*H*-imidazol-4-yl)propanoate (5 mmol) with cyclopropyl 4-fluorophenyl methanone (7.5 mmol) was performed as described above with NaH (10 mmol) being added in two portions.

The analytical data of the compounds obtained (mp, ¹H NMR, EI-MS, IR, TLC-R_f) are in agreement with those of ciproxifan prepared as described in literature [3].

References

- [1] X. Ligneau, J.-S. Lin, G. Vanni-Mercier, M. Jouvét, J. L. Muir, C. R. Ganellin, H. Stark, S. Elz, W. Schunack, J.-C. Schwartz, *J. Pharmacol. Exp. Ther.* **1998**, *287*, 658–666.
- [2] C. R. Ganellin, A. Fkyerat, B. Bang-Andersen, S. Athmani, W. Tertiuik, M. Garbarg, X. Ligneau, J.-C. Schwartz, *J. Med. Chem.* **1996**, *39*, 3806–3813.
- [3] H. Stark, B. Sadek, M. Krause, A. Hüls, X. Ligneau, C. R. Ganellin, J.-M. Arrang, J.-C. Schwartz, W. Schunack, *J. Med. Chem.* **2000**, *43*, in press.
- [4] C. Pasini, S. Coda, *Gazz. Chim. Ital.* **1957**, *87*, 1464–1477.
- [5] P. A. J. Janssen, C. van de Westeringh, A. H. M. Jageneau, P. J. A. Demoen, B. K. F. Hermans, G. H. P. Daele, K. H. L. Schellekens, C. A. M. van der Eycken, C. J. E. Niemegeers, *J. Med. Pharm. Chem.* **1959**, *1*, 281–297.
- [6] W. J. Close, *J. Am. Chem. Soc.* **1957**, *79*, 1455–1458.
- [7] J. W. ApSimon, D. G. Durham, A. H. Rees, *J. Chem. Soc., Perkin Trans. I* **1978**, 1588–1594.
- [8] J.-C. Schwartz, J.-M. Arrang, M. Garbarg, A. Quemener, J.-M. Lecomte, X. Ligneau, W. Schunack, H. Stark, K. Purand, A. Hüls, S. Reidemeister, S. Athmani, C. R. Ganellin, N. Pelloux-Léon, W. Tertiuik, M. Krause, B. Sadek, *Int. Pat. Appl.* WO 96/29 315. Sept. 26, **1996**.

Received: June 29, 2000 [FP501]

© WILEY-VCH Verlag GmbH, D-69451 Weinheim, 2000 – Printed in the Federal Republic of Germany

Alle Rechte, insbesondere die der Übersetzung in fremde Sprachen, vorbehalten. Kein Teil dieser Zeitschrift darf ohne schriftliche Genehmigung des Verlages in irgendeiner Form – durch Fotokopie, Mikrofilm oder irgendein anderes Verfahren – reproduziert oder in eine von Maschinen, insbesondere von Datenverarbeitungsmaschinen verwendbare Sprache übertragen oder übersetzt werden. – All rights reserved (including those of translation into foreign languages). No part of this issue may be reproduced in any form – photoprint, microfilm, or any other means – nor transmitted or translated into a machine language without the permission in writing of the publishers. – Von einzelnen Beiträgen oder Teilen von ihnen dürfen nur einzelne Vervielfältigungsstücke für den persönlichen und sonstigen eigenen Gebrauch hergestellt werden. Die Weitergabe von Vervielfältigungen, gleichgültig zu welchem Zweck sie hergestellt werden, ist eine Urheberrechtsverletzung. Der Inhalt dieses Heftes wurde sorgfältig erarbeitet. Dennoch übernehmen Autoren, Herausgeber, Redaktion und Verlag für die Richtigkeit von Angaben, Hinweisen und Ratschlägen sowie für eventuelle Druckfehler keine Haftung. This journal was carefully produced in all its parts. Nevertheless, authors, editors and publishers do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate. – Die Wiedergabe von Gerbrauchsamen, Handelsnamen, Warenbezeichnungen u. dgl. in dieser Zeitschrift berechtigt nicht zu der Annahme, daß solche Namen ohne weiteres von jedermann benutzt werden dürfen. Es handelt sich häufig um gesetzlich eingetragene Warenzeichen, auch wenn sie in dieser Zeitschrift nicht als solche gekennzeichnet sind. Druck und Buchbinder: Druck Partner Rübelmann GmbH, D-69502 Hemsbach. – Unverlangt zur Rezension eingehende Bücher werden nicht zurückgesandt.

For USA and Canada: Archiv der Pharmazie (ISSN 0365-6233) is published monthly. – Printed in the Federal Republic of Germany.

US Postmaster: Periodicals postage paid at Jamaica, NY 11431. Air freight and mailing in the USA by Publications Expediting Services Inc., 200 Meacham Ave., Elmont NY 11003.

Send address changes to: "Archiv der Pharmazie", c/o Publications Expediting Services Inc., 200 Meacham Ave., Elmont NY 11003
Valid for users in the USA: The appearance of the code at the bottom of the first page of an article in this journal (serial) indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition, however, that copier pay the stated per copy fee through the Copyright Clearance Center, Inc., for copying beyond that permitted by Sections 107 for 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective work, or for resale. For copying from back volumes of this journal see »Permissions to Photo-Copy: Publisher's Fee List« of the CCC.

Printed on chlorine- and acid-free paper/Gedruckt auf säurefreiem und chlorfrei gebleichtem Papier